CCL2与Schnitzler综合征系统性炎症的关联
研究比较Schnitzler综合征(SchS)患者与健康对照、银屑病及化脓性汗腺炎患者的血液指标,发现SchS患者CCL2显著升高,且与整体疾病活动度尤其骨痛正相关,与病程、丙种球蛋白病、中性粒细胞增多或皮肤病变无关。体外实验显示单核免疫细胞和成纤维细胞产生CCL2能力强,IL-1β和TNF-α是重要诱导因子。IL-1β阻断治疗1周内即降低CCL2血水平。
要点
- SchS患者CCL2水平显著升高,与整体疾病活动度尤其骨痛正相关。
- IL-1β和TNF-α是CCL2的重要诱导因子,TNF-α可增强IL-1β在成纤维细胞中的诱导作用。
- IL-1β阻断治疗开始后1周内即降低SchS患者CCL2血水平。
核心结论
- CCL2可能是导致骨改变的病理级联反应的重要组成部分,并可能是SchS疾病活动的合适标志物。
研究设计与样本
- 研究采用酶联免疫吸附试验(ELISA)定量比较SchS患者与健康对照、银屑病和化脓性汗腺炎患者的血液参数。
- 体外培养原代细胞,通过定量逆转录聚合酶链反应和ELISA分析CCL2表达。
主要发现
- CCL2在SchS患者中显著升高,其水平与整体疾病活动度正相关,尤其与骨痛正相关,但与病程、丙种球蛋白病、中性粒细胞增多或皮肤病变无关。
- 体外刺激实验显示单核免疫细胞和成纤维细胞具有强CCL2产生能力,上皮或内皮细胞则无。
- 在多种炎症介质中,仅IL-1β(免疫细胞、成纤维细胞)和肿瘤坏死因子(TNF)-α(成纤维细胞)是重要的CCL2诱导因子。
- TNF-α而非IL-17可增强IL-1β在成纤维细胞中的CCL2诱导效应;SchS患者CCL2水平与血清TNF-α和IL-1β水平均正相关。
- 治疗性IL-1β阻断在开始治疗后1周内即降低这些患者的CCL2血水平。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Schnitzler syndrome (SchS) is a rare autoinflammatory disease characterized by urticarial exanthema, bone and joint alterations, fever and monoclonal gammopathy, which manifest mostly in the second half of life. It involves overactivation of the interleukin (IL)-1 system, but the exact pathophysiological pathways remain largely unknown. OBJECTIVES: To identify and characterize the pathogenetic players in SchS. METHODS: Blood parameters were quantified in patients with SchS compared with healthy controls and patients with psoriasis and hidradenitis suppurativa using enzyme-linked immunosorbent assay (ELISA). CCL2 expression in cultured primary cells was analysed by quantitative reverse-transcriptase polymerase chain reaction and ELISA. RESULTS: CCL2, a chemoattractant for monocytic and further mononuclear immune cells, was found to be significantly elevated in patients with SchS. CCL2 levels showed a positive association with global disease activity, especially with bone pain, but not disease duration, gammopathy, neutrophilia or skin disease. In vitro stimulation assays demonstrated a strong CCL2 production capacity of mononuclear immune cells and fibroblasts, but not epithelial or endothelial cells. Among a range of inflammatory mediators, only IL-1β (immune cells, fibroblasts) and tumour necrosis factor (TNF)-α (fibroblasts) were important CCL2 inducers. TNF-α, but not IL-17, strengthened the CCL2-inducing effect of IL-1β in fibroblasts. Accordingly, CCL2 levels positively correlated with both TNF-α and IL-1β serum levels in patients with SchS. Therapeutic IL-1β blockade decreased CCL2 blood levels in these patients as early as 1 week after the initiation of treatment. CONCLUSIONS: CCL2 may be an important component of the pathogenetic cascade leading to bone alterations, and a suitable marker of disease activity in patients with SchS.
引用
- Krause K, Sabat R, Witte-Händel E, et al. Association of CCL2 with systemic inflammation in Schnitzler syndrome. Br J Dermatol. 2018. PMID: 30339714. doi:10.1111/bjd.17334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。